Maribavir for Prevention of CMV After Stem Cell Transplants

• Status: Completed
• Trial end date: 2006-04-05
• Target enrollment: 0
• Participant gender: All

Summary

Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Maribavir

Criteria

Inclusion Criteria:

• Allogeneic stem cell transplant recipient

• Recipient CMV seropositive

• Have transplant engraftment

• Able to swallow tablets

Exclusion Criteria:

• CMV organ disease

• HIV infection

• Use of other anti-CMV therapy post-transplant